This has reference to our disclosure dated November 19 2021 regarding the signing of an investment agreement with M/s. Immunoadoptive Cell Therapy Private Limited (ImmunoACT) an advanced cell and gene therapy company to acquire 26.62% stake (fully diluted basis) subject to completion of conditions precedent for a cash consideration of approximately Rs. 46.00 Crores.
In this regard we wish to update that the Company has paid the subscription amount of Rs.27.60 Crores (Rupees Twenty-Seven Crores and Sixty Lakhs only) as Tranche 1 Subscription Amount today (i.e. on December 09 2021). Along with the Company the senior management of the Company also paid the Tranche 1 Subscription Amount today.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
